Could severe COVID-19 be considered a complementopathy?

Lupus Sci Med. 2020 May;7(1):e000415. doi: 10.1136/lupus-2020-000415.

Authors

Katerina Chatzidionysiou¹, Elisabet Svenungsson², Francesca Faustini²

Affiliations

¹ Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden Aikaterini.Chatzidionysiou@ki.se.
² Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden.

No abstract available

Keywords: antibodies, antiphospholipid; cytokines; inflammation.

Publication types

Letter

MeSH terms

Animals
Betacoronavirus / isolation & purification*
COVID-19
Complement Activation* / drug effects
Complement Activation* / immunology
Complement Inactivating Agents* / immunology
Complement Inactivating Agents* / pharmacology
Coronavirus Infections* / immunology
Coronavirus Infections* / physiopathology
Coronavirus Infections* / therapy
Disseminated Intravascular Coagulation / immunology
Drug Discovery
Humans
Immunity, Innate / immunology
Inflammation / immunology
Pandemics*
Pneumonia, Viral* / immunology
Pneumonia, Viral* / physiopathology
Pneumonia, Viral* / therapy
SARS-CoV-2
Severity of Illness Index

Substances

Complement Inactivating Agents